Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3107513 | 0.85 | PDE10A (0.50) | PDE10A | |
| SCHEMBL3109695 | 0.78 | MAPT (0.44) | C5AR1PARP1TNKS2PARP2MAPT | |
| SCHEMBL14328064 | 0.76 | P2RX7 (0.49) | C5AR1PARP1TNKS2PARP2MAPT | |
| SCHEMBL2490202 | 0.75 | PARP1 (0.43) | C5AR1PARP1TNKS2PARP2 | |
| SCHEMBL3102345 | 0.73 | MAPT (0.40) | C5AR1PARP1TNKS2PARP2MAPT | |
| SCHEMBL13329339 | 0.73 | PARP1 (0.44) | C5AR1PARP1TNKS2PARP2MAPT | |
| SCHEMBL16518210 | 0.72 | PTGDR2 (0.54) | — | |
| SCHEMBL29330189 | 0.72 | PARP1 (0.46) | PARP1TNKS2PARP2MAPT | |
| SCHEMBL21807309 | 0.71 | PARP1 (0.43) | PARP1TNKS2PARP2MAPT | |
| SCHEMBL951733 | 0.71 | NR1H2 (0.47) | C5AR1PARP1TNKS2PARP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179173-A1 | SUBSTITUTED FUSED PYRIMIDINES AS ANTAGONISTS OF GPR105 ACTIVITY | MERCK FROSST CANADA LTD. (CA) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179173-A1 | SUBSTITUTED FUSED PYRIMIDINES AS ANTAGONISTS OF GPR105 ACTIVITY | GPR119, GPR35, GPR55 | C5AR1 824/4885PARP1 2453/4885TNKS2 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.